- Home
- TMO vs AMGN Comparison
TMO vs AMGN Comparison
Compare TMO & AMGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TMO
- AMGN
- Stock Information
- Founded
- TMO 1956
- AMGN 1980
- Country
- TMO United States
- AMGN United States
- Employees
- TMO N/A
- AMGN N/A
- Industry
- TMO Industrial Machinery/Components
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TMO Industrials
- AMGN Health Care
- Exchange
- TMO Nasdaq
- AMGN Nasdaq
- Market Cap
- TMO 175.3B
- AMGN 150.8B
- IPO Year
- TMO N/A
- AMGN N/A
- Fundamental
- Price
- TMO $539.30
- AMGN $293.75
- Analyst Decision
- TMO Buy
- AMGN Buy
- Analyst Count
- TMO 15
- AMGN 18
- Target Price
- TMO $584.79
- AMGN $326.94
- AVG Volume (30 Days)
- TMO 2.6M
- AMGN 2.8M
- Earning Date
- TMO 10-22-2025
- AMGN 10-29-2025
- Dividend Yield
- TMO 0.32%
- AMGN 3.22%
- EPS Growth
- TMO 7.24
- AMGN 110.88
- EPS
- TMO 17.30
- AMGN 12.23
- Revenue
- TMO $43,212,000,000.00
- AMGN $34,917,000,000.00
- Revenue This Year
- TMO $3.54
- AMGN $8.94
- Revenue Next Year
- TMO $4.83
- AMGN $1.69
- P/E Ratio
- TMO $31.18
- AMGN $24.17
- Revenue Growth
- TMO 2.04
- AMGN 12.88
- 52 Week Low
- TMO $385.46
- AMGN $253.30
- 52 Week High
- TMO $610.97
- AMGN $335.88
- Technical
- Relative Strength Index (RSI)
- TMO 69.85
- AMGN 58.82
- Support Level
- TMO $456.67
- AMGN $269.77
- Resistance Level
- TMO $487.99
- AMGN $301.53
- Average True Range (ATR)
- TMO 14.59
- AMGN 7.04
- MACD
- TMO 7.51
- AMGN 2.44
- Stochastic Oscillator
- TMO 90.48
- AMGN 77.30
About TMO Thermo Fisher Scientific Inc
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.